The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Status unconfirmed

Conditions studied: Metastatic Disease, Primary Tumor, Solid Malignancies

In brief

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to: 1. Diagnostic accuracy using pathologic correlation as gold standard measure 2. Short and long term event free and overall survival

Key facts

Study ID

NCT04492735

Run by

Roshni Dasgupta

People needed

45

Starts

2020-06-05

Expected to finish

2025-06-01

Last updated by the study team

2020-07-30

Who can join

Age: 0 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions.
• Diagnosis of primary or metastatic malignancy will be made by combination of:
• Clinical evaluation and physical exam
• Radiologic study including ultrasound, CT scan, and/or MRI
• Pathologic diagnosis after biopsy

You may not qualify if…

• Those patients and parents/guardians unwilling to provide consent/assent.
• Pregnant and/or women who are breast feeding.
• Patients with Iodine allergies

Where it is running

• Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.